EJXB Stock Overview
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Elekta AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr6.69 |
| 52 Week High | kr7.94 |
| 52 Week Low | kr5.99 |
| Beta | 1.03 |
| 1 Month Change | -3.65% |
| 3 Month Change | -2.04% |
| 1 Year Change | -8.87% |
| 3 Year Change | -41.62% |
| 5 Year Change | -35.84% |
| Change since IPO | 210.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| EJXB | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -4.3% | -4.0% | -1.2% |
| 1Y | -8.9% | -3.7% | 1.2% |
Return vs Industry: EJXB underperformed the German Medical Equipment industry which returned -3.7% over the past year.
Return vs Market: EJXB underperformed the German Market which returned 1.2% over the past year.
Price Volatility
| EJXB volatility | |
|---|---|
| EJXB Average Weekly Movement | 4.0% |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 9.8% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: EJXB has not had significant price volatility in the past 3 months.
Volatility Over Time: EJXB's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1972 | 4,584 | Gustaf Salford | elekta.com |
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care.
Elekta AB (publ) Fundamentals Summary
| EJXB fundamental statistics | |
|---|---|
| Market cap | €2.54b |
| Earnings (TTM) | €123.54m |
| Revenue (TTM) | €1.57b |
20.6x
P/E Ratio1.6x
P/S RatioIs EJXB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EJXB income statement (TTM) | |
|---|---|
| Revenue | kr18.22b |
| Cost of Revenue | kr11.32b |
| Gross Profit | kr6.90b |
| Other Expenses | kr5.47b |
| Earnings | kr1.43b |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
Jun 05, 2024
| Earnings per share (EPS) | 3.75 |
| Gross Margin | 37.88% |
| Net Profit Margin | 7.86% |
| Debt/Equity Ratio | 57.2% |
How did EJXB perform over the long term?
See historical performance and comparison